Showing 33–44 of 44 resultsSorted by popularity
Winstrol (Stanozolol) is a C17-alpha-alkylated DHT derivative with a pyrazole ring modification that significantly reduces SHBG levels and inhibits glucocorticoid receptors. Its 9-hour half-life supports research into lean muscle hardening and strength enhancement without aromatization.
MK-2866 (Ostarine) is a non-steroidal SARM that selectively agonizes androgen receptors in muscle and bone tissue with a Ki of 3.8 nM. Its 24-hour half-life provides steady receptor occupancy for investigating lean tissue preservation and muscle wasting prevention.
RAD140 is a potent non-steroidal SARM with a 60-hour half-life that selectively agonizes skeletal muscle androgen receptors with minimal prostate or sebaceous gland activity. It drives myofibrillar protein synthesis and exhibits neuroprotective properties.
Winstrol (Stanozolol) Injectable Suspension is a pyrazole-modified DHT derivative that binds microsomal androgen receptors and inhibits SHBG synthesis, increasing free androgen bioavailability. The injectable delivery provides a 24-hour half-life with superior bioavailability.
Primobolan (Methenolone Enanthate) is a mild injectable DHT derivative with a 1-methyl substitution that prevents aromatization while preserving clean anabolic signaling. The enanthate ester provides sustained release for long-term tissue preservation and nitrogen balance research.
M1T (17a-Methyl-1-testosterone) is a highly potent C17-alpha-alkylated DHT derivative that delivers exceptional anabolic signaling through direct androgen receptor activation. A primary research compound for studying extreme nitrogen retention and rapid muscle hypertrophy.
Halotestin (Fluoxymesterone) is an extremely potent C17-alkylated androgen featuring 9-alpha-fluoro and 11-beta-hydroxy modifications that maximize androgen receptor binding while preventing aromatization. A trusted compound for investigating central nervous system androgenic signaling.
Letrozole (Femara) is a non-steroidal Type II aromatase inhibitor that competitively coordinates with the CYP19A1 heme iron, reversibly blocking androgen-to-estrogen conversion. A high-potency research tool for achieving strong estrogen suppression.
Myostatin inhibitor SARM for muscle growth research. Study follistatin upregulation and AR activation.
Andarine (S4) is a tissue-selective SARM that binds the androgen receptor with high affinity and preferentially activates androgen response elements in skeletal muscle and bone over prostate tissue. Its 4-hour half-life requires optimized dosing protocols.
SR9009 is a Rev-ErbA nuclear receptor agonist that suppresses BMAL1 and CLOCK gene transcription to reprogram circadian metabolic rhythms. It upregulates mitochondrial biogenesis and fatty acid oxidation in skeletal muscle, functioning as an exercise mimetic.
Exemestane (Aromasin) is a steroidal Type I aromatase inhibitor that acts as a suicide substrate, irreversibly binding and permanently deactivating the CYP19A1 enzyme. With a 24-hour half-life, it produces marked and sustained estrogen suppression.
End of content
End of content
No products in the cart.
